Melbourne, Australia & Indianapolis, Indiana, U.S. | April 15, 2026
Telix Pharmaceuticals has announced a major clinical milestone with the first patient dosed in its pivotal Phase 3 IPAX-BrIGHT trial evaluating TLX101-Tx (¹³¹I-iodofalan) for the treatment of recurrent glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. This development marks the first radiopharmaceutical therapy to enter Phase 3 clinical development for glioblastoma, highlighting a significant advancement in neuro-oncology and targeted cancer therapies. The trial initiation reflects growing momentum in the use of precision radiopharmaceutical approaches to address critical unmet needs in oncology, particularly for patients who have limited treatment options after disease recurrence.
Pivotal Phase 3 Trial Targets High Unmet Need in Glioblastoma
The IPAX-BrIGHT trial is a global, multicenter, open-label study designed to evaluate the safety and efficacy of TLX101-Tx in combination with lomustine chemotherapy, compared to standard chemotherapy alone in patients with radiographically confirmed recurrent glioblastoma at first recurrence. The first patient was treated at Austin Health in Melbourne under the supervision of leading clinical investigators, marking the operational launch of this registration-enabling study.
Glioblastoma remains a devastating disease with very limited therapeutic advancements over the past 25 years, and currently, there is no universally accepted standard of care for recurrent cases. By advancing into Phase 3, Telix aims to generate robust clinical evidence that could support future regulatory approvals and transform treatment paradigms for this patient population.
Radiopharmaceutical Innovation Enables Targeted Brain Tumor Therapy
Advertisement
TLX101-Tx represents a novel radiopharmaceutical therapy that targets the L-type amino acid transporter 1 (LAT1), enabling it to cross the blood-brain barrier and deliver targeted radiation directly to tumor cells. This mechanism differentiates it from conventional therapies by offering a highly selective and localized treatment approach, minimizing damage to surrounding healthy tissue. The therapy builds upon promising results from earlier studies, including IPAX-1 and IPAX-Linz trials, which demonstrated encouraging median overall survival outcomes of up to 13 months from treatment initiation and extended survival from initial diagnosis.
Additionally, an early access program in Europe has further supported the therapy’s potential clinical utility, with multiple patients receiving treatment in real-world settings. The integration of TLX101-Px PET imaging for patient selection and response assessment further strengthens the precision medicine approach, enabling better tumor characterization and treatment monitoring.